Tag: ELAN
High Response to PD-1 Therapy Seen in Unresectable Desmoplastic Melanoma
Complete response rate was 37 percent, and post-hoc end point of objective response rate was 89 percent
Presurgical Immunotherapy Offers Long-Term Benefit in Melanoma
80 percent of adult patients with stage III/IV resectable melanoma remained event-free at four years from the start of neoadjuvant systemic treatment
Immune Checkpoint Inhibitor Affordability Tied to Widening Survival Disparity
Introduction of immune checkpoint inhibitors linked to widening disparity for those with private insurance versus those without insurance
AI Better for Tumor-Infiltrating Lymphocyte Quantification in Melanoma Than Traditional Methods
Machine learning algorithm has superior reproducibility and prognostic associations compared with traditional pathologist-read methods
Mismatch Repair Germline Pathogenic Variants Could Predispose to Uveal Melanoma
Twenty-one pathogenic variants found in clinically relevant genes, with an enrichment in mismatch repair genes
Mitochondrial Genetics Key to Metastatic Melanoma Immunotherapy Resistance
Patients belonging to haplogroup T exhibit unique nivolumab-resistant baseline peripheral CD8+ T-cell repertoire
